COVID-19 Impact on Global Preeclampsia Diagnostics Market by Test Type(Blood Test and Urine Analysis); By Product Type (Instruments and Consumables); By End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others.) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

May 2022 | 291 pages | ID: CDDA909645B6EN
Fatpos Global

Abstracts

COVID-19 Impact on Global Preeclampsia Diagnostics Market by Test Type(Blood Test and Urine Analysis); By Product Type (Instruments and Consumables); By End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others.) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

Contents

1. EXECUTIVE SUMMARY

2. PREECLAMPSIA DIAGNOSTICS MARKET

2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. RESEARCH METHODOLOGY

3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. AVERAGE PRICING ANALYSIS

5. MARKET DYNAMICS

5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends

6. CORRELATION & REGRESSION ANALYSIS

6.1. Correlation Matrix
6.2. Regression Matrix

7. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE

8. RISK ANALYSIS

8.1. Demand Risk Analysis
8.2. Supply Risk Analysis

9. PREECLAMPSIA DIAGNOSTICS MARKET ANALYSIS

9.1. Porters Five Forces
  9.1.1. Threat of New Entrants
  9.1.2. Bargaining Power of Suppliers
  9.1.3. Threat of Substitutes
  9.1.4. Rivalry
9.2. PEST Analysis
  9.2.1. Political
  9.2.2. Economic
  9.2.3. Social
  9.2.4. Technological

10. PREECLAMPSIA DIAGNOSTICS MARKET

10.1. Market Size & forecast, 2019A-2030F
  10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. PREECLAMPSIA DIAGNOSTICS MARKET: MARKET SEGMENTATION

11.1. By Regions
  11.1.1. North America:(U.S. and Canada)
    11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
    11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
    11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
    11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
    11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. PREECLAMPSIA DIAGNOSTICS MARKET: MARKET SEGMENTATION

12.1. By test type: Market Share (2020-2030F)
  12.1.1. Blood test, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12.1.2. Urine analysis, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By product type: Market Share (2020-2030F)
  12.2.1. instruments, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12.2.2. consumables, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. By end-user: Market Share (2020-2030F)
  12.3.1. hospitals, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12.3.2. specialty clinics, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12.3.3. diagnostic centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12.3.4. others, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

13. COMPANY PROFILE

13.1. Bayer AG
  13.1.1. Company Overview
  13.1.2. Company Total Revenue (Financials)
  13.1.3. Market Potential
  13.1.4. Global Presence
  13.1.5. Key Performance Indicators
  13.1.6. SWOT Analysis
  13.1.7. Product Launch
13.2. Roche
13.3. PerkinElmer
13.4. DRG INSTRUMENTS GMBH
13.5. Thermo Fisher Scientific
13.6. Diabetomics, Inc.
13.7. Metabolomic Diagnostics Ltd.
13.8. Sera Prognostics
13.9. Siemens Healthineers
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable